Surgical treatment of Ebstein's anomaly. Early and late results in seven consecutive cases

Thrombolytic therapy for obstruction of mechanical prosthetic valves

This report describes two patients who were treated for obstruction of St. Jude tricuspid valve prostheses. In the patient with the hypereosinophilic syndrome, right heart failure developed 15 days after valve replacement. The other patient had symptoms of right heart failure for 8 weeks; these occurred 15 months after valve implantation. In both patients, thrombolytic therapy was successful and without major sequelae. Herein we review the literature on the use of thrombolysis for obstructed mechanical prosthetic valves and completely summarize the English literature; the efficacy of thrombolysis for obstructed prosthetic valves and the associated morbidity and mortality are emphasized. Recommendations for thrombolysis in clinical practice are provided.

The risks and benefits of thrombolytic therapy in acute aortic and mitral prosthetic valve dysfunction: report of a case and review of the literature

A patient with acute thrombosis of a St. Jude mitral prosthesis was treated with streptokinase with initial success. Subsequent recurrent thrombosis and embolism prompted operative revision. Because the use of thrombolytic agents in this setting is somewhat controversial, we searched the literature for all reports of aortic or mitral prosthetic valve dysfunction treated this way. The cases of 58 patients treated 62 times were reviewed for efficacy of therapy and morbidity. Thrombolytic therapy may be useful in patients with prosthetic valve thrombosis causing critical hemodynamic compromise. It is frequently the only treatment needed. Further, it may help reduce operative risk for those patients in whom complete resolution is not possible. The incidence of systemic embolism is 18%, however, neurological events are usually limited and transient.

Thrombolytic therapy for prosthetic cardiac valve thrombosis

To determine the efficacy and safety of thrombolytic therapy for prosthetic valve thrombosis, a composite series of 41 patients who received either streptokinase or urokinase intravenously for this disorder were analyzed. The series comprised 3 patients treated at Rhode Island Hospital and 38 previously reported on. Short-term success was achieved in 32 patients (78%). Prosthetic valve thrombosis recurred in seven (22%) of the successfully treated patients, four of whom were retreated with thrombolytic therapy. A favorable clinical outcome was observed in each. Fever and venipuncture bleeding were the most frequent side effects. Systemic embolization occurred in 4 (15%) of 26 patients with either aortic or mitral prosthetic valve thrombosis. None of these latter patients experienced a permanent neurologic or circulatory deficit. It is concluded that thrombolytic therapy is of value in the treatment of prosthetic valve thrombosis.

Failure of mechanical valves in Ebstein's malformation

Five patients with Ebstein's malformation were operated on with closure of the atrial septal defect and implantation of a mechanical prosthesis at the right atrioventricular junction. The 4 patients who survived showed an excellent early recovery. Three of the patients noticed the disappearance of the valve clicks 6 months after the operation. At re-examination using echophonocardiography, peripheral dye dilution curves and catheterization, these valves were found to be stuck in the open position in 2 patients and in the closed position in 1 patient. The last patient had a paravalvar channel supplying blood into the right ventricle. One patient who had a St. Jude prosthesis was doing excellently 4 years postoperatively and the valve was functioning well. Two years after the operation, the other patient with a St. Jude valve again noticed valve clicks after over 1 year of silence. Examination revealed the prosthesis to be functioning normally. The totally occluded Björk-Shiley prosthesis (10 years postoperatively) was excised at re-operation and replaced by an Ionescu-Shiley bioprosthesis. The patient with a jammed Björk-Shiley prosthesis (10 years postoperatively) declined a re-operation and is doing well, albeit under close observation.

Late (5 to 132 months) clinical and hemodynamic results after either tricuspid valve replacement or anuloplasty for Ebstein's anomaly of the tricuspid valve

Late clinical and hemodynamic observations are described in 6 patients who had either tricuspid valve anuloplasty (TVA) (2 patients) or tricuspid valve replacement (TVR) (4 patients) 5 to 132 months earlier for Ebstein's anomaly of the tricuspid valve unassociated with right ventricular outflow obstruction. Of the 6 patients, 4 had improved postoperatively by 1 New York Heart Association functional class and 2 had improved by 2 functional classes. The cardiothoracic ratio decreased 5 to 12 months after either TVR or TVA in all 6 patients (from a mean of 0.72 to 0.62). Repeat cardiac catheterization 5 to 12 months after TVA or TVR disclosed that the right atrial mean pressure had increased from a median of 4.0 to 10.5 mm Hg (p = 0.05); the right ventricular peak systolic pressure had increased from 19.0 to 31.5 mm Hg (p = 0.02); the right ventricular end-diastolic pressure had increased from 5.0 to 9.0 mm Hg (p = 0.05); the systemic arterial peak systolic pressure had increased from 115 to 123 mm Hg (p = 0.03); and the cardiac index had increased (in all 4 patients in whom both pre- and postoperative values were available) from 1.7 to 2.9 liters/min/m2 (p = 0.06). Thus, the tricuspid valve operations in our 6 patients with Ebstein's anomaly were associated with a decrease in symptoms of cardiac dysfunction, a decrease in cardiac size, an increase in cardiac index and an increase in right ventricular and right atrial pressures. The elevation of the right atrial pressures postoperatively may have resulted from increased right ventricular filling pressures, persistent tricuspid regurgitation or bioprosthetic stenosis.

Follow-up assessment of St. Jude Medical prosthetic valve in the tricuspid position: clinical and hemodynamic results

Seven patients underwent postoperative right heart catheterization implantation of the St. Jude Medical prosthetic valve in the tricuspid position. Six patients were in atrial fibrillation at catheterization, and 1 was in normal sinus rhythm. At postoperative catheterization, the mean right atrial pressure ranged between 4 and 16 mm Hg (mean, 9.7 mm Hg); right ventricular systolic pressure was normal in 1 patient, mildly elevated (less than 50 mm Hg) in 4 patients, and moderately elevated (65 and 70 mm Hg) in 2. The cardiac output ranged between 3.0 and 7.0 L/min (mean, 4.2 L/min). There was no end-diastolic gradient across the St. Jude Medical prosthesis in 6 patients. The other patient had a gradient of 2 mm Hg across the valve when cardiac output was 7.0 L/min. On fluoroscopy, both discs demonstrated full excursion in all patients. These data demonstrate that a normally functioning St. Jude Medical valve in the tricuspid position does not create obstruction to forward flow, and they support use of this prosthesis in patients with tricuspid valve disease.

Valve replacement for Ebstein's anomaly of the tricuspid valve. Early and long-term results of eight cases

The role of valve replacement in the treatment of Ebstein's anomaly of the tricuspid valve remains controversial. Since 1965, eight patients with Ebstein's anomaly ranging in age from seven to 22 years of age (mean 13 years) have undergone tricuspid valve replacement (TVR) in our institution. Seven were in functional class 3 or 4 (NYHA), while one was in class 2, but had an increase in cardiac size. All of these eight patients showed moderate to severe cardiomegaly (cardiothoracic ratio: 54-75 percent). The valve was placed on the tricuspid annulus in seven of the eight cases, the exception being one case in which it was placed above the coronary sinus. Seven artificial prostheses (two Starr-Edwards, one Harken, one Kay-Shilley and three Wada-Cutter) and one porcine valve (Hancock) were used. There was one operative death in an early case due to postoperative complete heart block. Follow-up (range three to 18 years) of the other seven survival patients showed three late deaths; the first a pulmonary embolus 2.6 years after TVR; the second with congestive heart failure two years following the operation; and the third with arrhythmias five years after TVR. The remaining four patients are now in functional class 1 (three cases) and class 2 (one case). Valve replacement for Ebstein's anomaly can produce good clinical improvement and provide excellent long-term results.

Tricuspid valve replacement for Ebstein's anomaly. A 19 year review of the first case

Images